Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sanofi - American Depositary Shares
(NQ:
SNY
)
49.22
-0.13 (-0.26%)
Streaming Delayed Price
Updated: 12:54 PM EDT, Jul 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades.
July 26, 2025
You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.
Via
The Motley Fool
Topics
Artificial Intelligence
Retirement
Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel
July 25, 2025
Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.
Via
Benzinga
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates
July 24, 2025
Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose preclinical studies.
Via
Benzinga
Why Thermo Fischer Stock Is Rising Wednesday
July 23, 2025
Thermo Fisher beat Q2 estimates, raised its 2025 guidance, and announced a CFO transition as easing tariffs support an improved outlook.
Via
Benzinga
Topics
World Trade
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
July 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Humana Moves To Cut Prior Authorization Delays, Streamline Care Approvals
July 22, 2025
Humana will cut prior authorizations, launch a gold card program, and speed up electronic approvals to improve care access and transparency by 2026.
Via
Benzinga
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US
July 22, 2025
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs.
Via
Benzinga
Topics
Government
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
July 22, 2025
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
July 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
GSK Seeks FDA Nod To Broaden RSV Vaccine For Younger At-Risk Adults
July 15, 2025
FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the first half of 2026.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sanofi - SNY
July 14, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony
July 11, 2025
Delaware's top court reversed a ruling that allowed expert testimony in Zantac cancer lawsuits, citing improper legal standards by the trial judge.
Via
Benzinga
Topics
Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
July 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Dow Futures Edge Up As Trump Prepares More Tariff Letters: Freeport, UnitedHealth, Meta, Novo Nordisk, AstraZeneca Among Stocks In Focus
July 09, 2025
While Dow Jones futures edged up by 0.17% at the time of writing, the S&P 500 futures were up 0.15%.
Via
Stocktwits
Topics
ETFs
Government
Stocks
Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst
July 08, 2025
Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.
Via
Benzinga
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot
July 07, 2025
Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
Via
Investor's Business Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
July 06, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
July 03, 2025
FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 30, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
June 28, 2025
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.
Via
MarketBeat
Why This Biotech Stock Just Doubled In A Single Day
June 26, 2025
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 26, 2025
Via
ACCESS Newswire
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
June 25, 2025
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 25, 2025
Via
ACCESS Newswire
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
June 25, 2025
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 24, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
June 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Why Is Cidara Therapeutics Stock Trading Higher On Monday?
June 23, 2025
Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
37
38
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.